BREAKING: Johnson & Johnson says single-shot vaccine is 85 percent effective at preventing severe Covid cases, but weaker against South African variant

To ensure delivery to your inbox add email@mail.nbcnews.com to your contacts | View in browser Add NBC News to your contacts Unsubscribe from this email

Jan 29, 2021 BREAKING: Johnson & Johnson says single-shot vaccine is 85 percent effective at preventing severe Covid cases, but weaker against South African variant A single injection of Johnson & Johnson's Covid-19 vaccine is effective in preventing moderate to severe illness, the company reported Friday. The company is poised to ask the Food and Drug Administration for emergency use authorization as early as next week, and the agency could give the vaccine the go-ahead by the end of February. Results from the Phase 3 trial found that the vaccine was 85 percent effective overall at preventing severe disease, but varied by region. Overall, Johnson & Johnson's results for a single shot are not as strong as those from a double shot of Pfizer and Moderna, which each had exceptionally efficacy high levels. Those vaccines have been shown to be about 95 percent effective against symptomatic Covid-19, when given in two shots about a month apart. Read More Get the NBC News Mobile App Follow NBC News Check out all of NBCNEWS Newsletters here. Update Preferences | Unsubscribe | Contact | Privacy Update Preferences Unsubscribe Contact Privacy